NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
5 trialsNCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT01683994 2019-11-08
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01866293 2017-08-30
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed